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Edited by Robert BaroukiAbstract Oxygen is an essential element in the survival of com-
plex organisms, however the level of oxygen, low or high, can be
a source of stress depending on the biological context. Low levels
of oxygen in tissues (hypoxia) can be the consequence of a num-
ber of pathophysiological conditions including ischemic disorders
and cancer while relative, higher levels (hyperoxia) can lead to
retinopathy of prematurity. The local oxygen environment and
oxygen consumption dictate vascular homeostasis, vaso-prolifer-
ation and vaso-cessation, which is deregulated in these diseases
through oxygen-dependent growth factors. In this review, we will
introduce aspects of the physiology and biology of oxygen partial
pressure and the molecular mechanisms implicated in oxygen
sensing. We will outline the regulation and function of the key
operator in cellular signalling of hypoxia, the transcription fac-
tor, hypoxia-inducible factor. In addition, we will focus on cancer
cell hypoxia and on its role in driving cell metabolism, pH regu-
lation and survival.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Through evolution living organisms have been required to
adapt to changes in atmospheric concentrations of carbon
dioxide, nitrogen and oxygen. Some four billion years ago
the earth’s atmosphere was composed of a ratio of CO2:N2:O2
of 98:1.9:0 and today this ratio is 0.03:79:21. This progressive
change from an atmosphere lacking oxygen to one relatively
rich in oxygen has been accompanied by a substantial increase
in the complexity of living organisms. Such organisms may still
be required to adapt to variations in gaseous partial pressures
in situations such as with increasing altitude. The ‘‘thinning of
air’’, with increasing altitude that leads to a decrease in the
amount of available oxygen, is a stress situation that can,
depending on the altitude, result in mountain sickness. High
altitude dwellers are subject to carotid body (the peripheral
oxygen sensing organ) tumours associated with mutations in
a tumour suppressor gene, succinate dehydrogenase D. The in-
creased penetrance and severity of these tumours in this popu-*Corresponding author. Fax: +33 4 92 03 12 35.
E-mail address: brahimi@unice.fr (M.C. Brahimi-Horn).
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In mammals an increase in altitude results in an initial physio-
logical response that increases the rate and depth of breathing.
This response is followed by a molecular adaptive response
that implicates the transcription factor hypoxia-inducible fac-
tor (HIF). This factor modiﬁes expression of a myriad of genes
including that coding for erythropoietin (Epo). Epo is familiar
to the sporting world for its capacity to increase the number of
red blood cells, which thereby increases the oxygen carrying
capacity of the blood circulation.
Low levels of oxygen in tissues (hypoxia) also arise in nor-
mal development and as a consequence of a number of patho-
physiological conditions where there is a diminished oxygen
supply due to a defective vasculature. Such conditions include
ischemic disorders (cerebral or cardiovascular), diabetes, ath-
erosclerosis, inﬂammatory diseases, psoriasis, pre-eclampsia,
chronic obstructive pulmonary disease and cancer. In these
conditions HIF initiates angiogenesis, an adaptive response
that promotes neo-vascularization in zones of defective supply,
which is aimed at re-establishing adequate re-oxygenation. Ini-
tiation of angiogenesis and vascular remodelling implicates
HIF-mediated expression of the gene products, VEGF-A and
Angiopoı¨etin-2 (Ang-2), two key angiogenic factors [2].2. Tissue diﬀusion of oxygen and tumour hypoxia
The blood circulation carries oxygen to tissues and a physi-
ological tissue distribution of oxygen occurs as a result of pro-
gressive consumption of the oxygen in the blood circulation as
it passes through diﬀerent organs. The oxygen partial pressure
(pO2) of inspired air is around 160 mmHg at sea level (Fig. 1).
This drops progressively ﬁrst in the lungs; in part due to water
vapour and diﬀusion, then in the blood ﬂowing from the alve-
olar capillaries that carry the oxygen, at a pO2 of around
104 mmHg, towards organs and tissues for their oxygenation.
A further drop in the pO2 is observed in the venous system.
The pO2 of a given tissue depends on the type of organ, rat
spleen has a measured pO2 of around 16 mmHg, while the thy-
mus was measured at 10 mmHg [3]. This ‘‘normal’’ tissue pO2
can be considered as ‘‘hypoxic’’ from a molecular standpoint.
The low vascularization of the rat retina also makes it rela-
tively hypoxic (2–25 mmHg) [4] while tissues of the rat brain
have been reported to be even more hypoxic, 0.4–8.0 mmHg,
depending on the location [5]. The diﬀusion distance of oxygen
in a tissue is approximately 100–200 lm and an oxygen partial
pressure of almost zero has been reported at only 100 lm fromblished by Elsevier B.V. All rights reserved.
Fig. 1. Physiological and pathophysiological oxygen partial pressures (pO2). The pO2 of inspired air drops progressively as oxygen passes from the
lungs into the circulation, which irrigates the tissues of major organs, and then in the venous system before re-oxygenation in the lungs. The pO2 of
solid tumours (insert) is generally low compared to that of non-malignant tissues.
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poxia relative to the corresponding normal tissue (Fig. 1)
and diﬀusion of oxygen may be as low as 70 lm [8]. This is ex-
plained by the rapid proliferation of the tumour mass that dis-
tances the cells from the oxygen carrying vasculature but is
also the result of the formation of a vascular system that is dis-
torted and irregular, and thus ineﬃcient in oxygen transport.
The degree of hypoxia is variable within tumours and between
the tumour type, and is often associated with central necrotic
regions. It can be measured using chemical markers such as
pimonidazole hydrochloride or EF5 or with O2 microelec-
trodes or optical pO2 measuring devices. The detection of hyp-
oxic zones in tumours in patients can also be performed usingFig. 2. Immunoﬂuorescent detection of nuclear HIF-1a in cells exposed to hy
hypoxic (right panels) conditions and stained for nuclei (DAPI) (upper panepositron emission tomography (PET) after injection to patients
of [ﬂuorine-18] misonidazole (FDG) [9]. The resistance of tu-
mours to radio- and chemo-therapy has been directly attrib-
uted to the hypoxic nature of tumours and thus associated
with an unfavourable clinical outcome.3. The hypoxia-inducible factor the key operator in hypoxia
signalling
At a molecular level, a cellular hypoxic stress initiates a
number of adaptive responses that are the direct result of the
intervention of the transcription factor HIF. The inductionpoxia. Cultured HeLa cells were incubated in normoxic (left panels) or
ls) or for HIF-1a (lower panels).
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acute hypobaric hypoxia, was reported in 1991 in liver cells
incubated under hypoxic conditions [10]. HIF-1 was subse-
quently identiﬁed to bind to the Epo gene and to induce its
transcription, and thus, to increase the amount of its protein
product. It is now known that HIF is composed of an a and
b subunit and that HIF-a is not detected in the presence of
oxygen, normoxia, but detected under limiting, hypoxic oxy-
gen concentrations (Fig. 2). In contrast, HIF-b is not oxy-
gen-regulated and is constitutively present. While HIF-a is
detected in many cell culture systems at a cutoﬀ of around
5% oxygen (40 mmHg) most experiments performed with cul-
tured cells are undertaken at between 1% and 2% oxygen (8–
16 mmHg), which can be considered as hypoxic but not as
hypoxic as in many tumour cells. Under these conditions
HIF-a is detected in the nucleus of cells after only a few hours
(Fig. 2). The return of cells to sea level atmospheric oxygen
conditions (21%), normoxia, results in a loss of detectable
HIF-a in only a matter of minutes due to rapid degradation
by the proteasomal system (Fig. 3). In contrast, in hypoxia
HIF-a is stable, binds its partner HIF-b, and together they
bind to a hypoxia-response element (HRE) in target genes,
associate with co-activators such as CBP/p300 and activate
or suppress the transcription of as many as 70 genes implicated
in a myriad of function such as metabolism, angiogenesis,
invasion/metastasis and cell survival/death (Fig. 3).4. Regulation of the stability and activity of the hypoxia-
inducible factor
The molecular mechanisms behind the ephemeral nature of
HIF-a remained a mystery for about 10 years until it was dem-Fig. 3. Degradation and activation of the hypoxia-inducible factor-1a (HIF
transcription factor HIF is composed of an alpha and beta subunit. Under atm
are constitutively expressed. Whilst HIF-1a is rapidly degraded by the 26S
levels of oxygen (hypoxia) HIF-1a escapes degradation, associates with HIF-1
genes. Recruitment of co-activators such as CBP/p300 then results in transcri
metabolism, angiogenesis, invasion/metastasis and cell survival/death.onstrated that oxygen-requiring hydroxylases regulate not
only the stability but also the transcriptional activity of HIF.
The dioxygenase prolyl hydroxylase domain (PHD) protein
hydroxylates HIF-a on two proline residues. This posttransla-
tional modiﬁcation earmarks HIF-a for recognition by the von
Hippel–Lindau (VHL) ubiquitin E3 ligase complex and for
subsequent polyubiquitination that drives HIF-a to destruc-
tion through the 26S proteasomal system (Fig. 4). PHD pro-
teins exist in three isoforms and their corresponding genes
phd2 and phd3, but not phd1, are themselves HIF-targets. Thus
they are auto-regulated in hypoxia through increased expres-
sion of their protein products. This response guarantees rapid
and optimal degradation of HIF-a on return of cells to nor-
moxia. Another dioxygenase termed factor inhibiting HIF-1
(FIH-1) hydroxylates an N-terminal asparagine residue that
renders HIF inactive by abrogating binding to necessary co-
activators such as CBP (CREB binding protein) and its par-
alog p300, which are also histone acetyltransferases (Fig. 4).
Thus, a double lock of posttranslational hydroxylation is
responsible for primary control of HIF stability and activity.
Recent reviews, describing in further detail the properties
and functions of the PHDs, have been published by our group
and by others [11,12].
However, regulation of HIF-a also involves interaction with
a number of other proteins; some of which lead to its post-
translational modiﬁcation [13]; in particular phosphorylation
of HIF-a has been shown to promote transcriptional activity.
Interaction with proteins including the cellular chaperones
such as heat shock protein 90 (Hsp90) can regulate stability
[14]. Hsp90 stabilises HIF-1a by excluding interaction with
receptor of activated protein C kinase (RACK1) that recruits,
in an oxygen-independent manner, VHL. Hsps have been re-
ported to be up-regulated in hypoxia through HIF-mediated-1a) transcription factor in normoxia and hypoxia, respectively. The
ospheric levels of oxygen (normoxia) the HIF-1a and HIF-1b subunits
proteasomal system, HIF-1b remains constant. In contrast, under low
b and together they bind to hypoxia-response elements (HRE) in target
ptional activation of multiple target genes involved in functions such as
Fig. 4. The mechanisms of oxygen-mediated posttranslational regulation of the stability and activity of HIF-1a. Under atmospheric levels of oxygen
(normoxia) the HIF-1a protein is constitutively expressed but rapidly hydroxylated by the oxygen-sensor molecules prolyl hydroxylase domain
(PHD) and factor-inhibiting HIF-1 (FIH). Proline hydroxylation (P-OH) initiates interaction with the von Hippel–Lindau (VHL) ubiquitin E3 ligase
complex leading to ubiquitination of HIF-1a. Posttranslational modiﬁcation of proteins with chains of ubiquitin drives proteins to destruction by the
26S proteasomal system. Asparagine hydroxylation (N-OH) of HIF-1a prevents CBP/p300 co-activator interaction thereby repressing transcription
of target genes.
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tion factor heat shock factor, an action that not only reveals
a link between the oxygen-sensing and heat shock pathways
but also suggests a role for Hsps in protection from hypoxic
cell death [15].
The ﬁne-tuning of speciﬁc gene activation by HIF may result
from both isoform speciﬁcity and from the structural bi-func-
tional nature of the two transcriptional activation domains
(TAD) of HIF-a. In fact three isoforms of HIF-a, numbered
from one to three, and several splice variants of each exist.
There is increasing evidence to suggest that speciﬁc genes
may be activated by one or the other or several isoforms
[16–20]. These isoforms hold considerable sequence and struc-
tural homology and their stability and activity are similarly
regulated (For a diagrammatical representation of the diﬀerent
isoforms see [21]). In addition, HIF-1a and HIF-2a posses two
distinct TAD, where only one is regulated by FIH. Thus, the
TAD can respond diﬀerentially, according to the oxygen gra-
dient in tumours, in activating speciﬁc genes [22].5. The predilection of cancer cells for anaerobic glucose
metabolism
Compared to non-malignant tissues tumours in general have
a high rate of glucose uptake accompanied by elevated glucose
consumption through glycolysis [7]. As mentioned above, this
metabolic characteristic of tumours has been put into clinical
application through the detection by PET of FDG, a non-met-
abolisable glucose analogue that accumulates in solid tumours.
PET-FDG analysis is considered to be important in predicting
the aggressivity of a wide range of types of tumours. In the1850s, Louis Pasteur showed that aerating yeast, a facultative
anaerobe, leads to an increase in growth but a decrease in fer-
mentation, the ‘‘Pasteur eﬀect’’. So for biomass production
yeast are incubate in oxygenated conditions but for ethanol
production oxygen is made limiting. In the 1920s, Otto War-
burg discovered that tumours in contrast to non-malignant tis-
sue use a shortcut pathway for glucose metabolism in
converting glucose to pyruvate and then to lactic acid. Non-
malignant cells also convert glucose to pyruvate but in contrast
then metabolise pyruvate through the tricarboxylic acid (TCA)
cycle and oxidative phosphorylation (OXPHOS) in mitochon-
dria to form CO2 (Fig. 5). The latter mitochondrial pathway
requires oxygen and is much more eﬃcient in ATP production;
38 versus 2 ATP molecules per molecule of glucose. Surpris-
ingly, even in the presence of plentiful amounts of oxygen tu-
mour cells adopt the shortcut pathway a phenomenon known
as the ‘‘Warburg eﬀect’’. Knowing that tumour cells have a
high proliferation rate that requires considerable energy this
phenomenon is paradoxical. It is only now that the global
mechanism behind the cancer cell predilection for glucose
metabolism to lactic acid is starting to be understood and that
HIF is surfacing as one of the major actors (Fig. 6). HIF acts
basically in two ways; promoting anaerobic glucose metabo-
lism and repressing or rendering more eﬃcient mitochondrial
respiration. The genes coding for certain glucose transporters
and for enzymes of the glycolytic pathway are among the many
genes that are directly up-regulated by HIF. The conversion of
pyruvate to lactic acid is also enhanced by up-regulation of the
enzyme lactate dehydrogenase A (LDH-A), the enzyme that
catalyses pyruvate conversion to lactic acid [23]. Oncogenes,
such as Ras [24], c-myc [18,25], and the protein kinase Akt
[26,27], that promote cell survival are also responsible for the
Fig. 5. Tumour cells switch from aerobic to anaerobic glucose metabolism despite the lower energy yield. Non-malignant and malignant cells take-up
glucose from the blood stream via membrane glucose transporters (Glut) and metabolize glucose through the glycolytic pathway to form pyruvate.
Pyruvate in non-malignant cells enters the mitochondrial tricarboxylic acid cycle (TCA) and oxygen-requiring oxidative phosphorylation (OXPHOS)
to produce CO2 and 38 molecules of ATP. In contrast malignant cells convert pyruvate to lactic acid to produce two molecules of ATP.
Fig. 6. The multiple mechanisms through which HIF drives the switch to anaerobic glucose metabolism in tumour cells. Hypoxia stablized HIF-a
associates with constitutive HIF-b to bind and transcriptionally activate target genes that code for glucose transporters (Glut), glycolytic enzymes,
and lactate dehydrogenase-A (LDH-A). HIF-a/b also represses mitochondrial glucose metabolism through transcriptional activation of the gene
coding for pyruvate dehydrogenase kinase 1 (PDK1), an inhibitor of pyruvate dehydrogenase (PDH) that drives pyruvate into the tricarboxylic acid
cycle (TCA). Oncogenes (c-myc), the protein kinase Akt and tumour suppressor genes (p53) can also modulate cancer cell metabolism where c-myc
up-regulates glycolytic enzymes and mitochondrial biogenesis and p53 tips the balance toward mitochondrial metabolism via activation of synthesis
of cytochrome c oxidase 2 (SCO2). HIF-a/b also makes mitochondrial OXPHOS more eﬃcient by modulating the levels of COX (complex IV)
proteins of the electron transport chain (ETC). The functioning of the TCA cycle also inﬂuences the activity of PHDs and FIH hydroxylases that
regulate HIF-a since it produces the co-substrate 2-oxoglutarate (2-OG)(a-ketoglutarate) that is required for enzyme activity. In addition, the
succinate (S) and fumarate (F) produced by the TCA cycle give rise to feedback inhibition of PHDs.
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on HIF and HIF-target genes. c-myc was found to induceup-regulation of the glucose transporter GLUT1 and several
glycolytic enzymes as well as LDH-A. The tumour suppressor
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mitochondrial metabolism by slowing glycolysis. Regulation
of glycolysis occurs though the induction by p53 of the
TP53-induced glycolysis and apoptosis regulator (TIGAR) gene
that decreases the level of fructose-2,6-bisphosphate resulting
in inhibition of glycolysis [28] and through negative regulation
of the glycolytic enzyme phosphoglycerate mutase (PGM) [29].
Repression of pyruvate metabolism through mitochondrial
respiration provides a mitochondrial bypass mechanism that
promotes anaerobic glucose metabolism but also leads to the
sparing of oxygen. This occurs though HIF activation of the
expression of pyruvate dehydrogenase kinase 1 (PDK1) that
inhibits pyruvate dehydrogenase (PDH) [30,31], the enzyme
that converts pyruvate to acetyl-CoA for entry into the TCA
cycle. LDH-A knockdown not only suppresses lactate produc-
tion in tumour cells but increases oxygen consumption and
OXPHOS activity, thereby tipping back the glycolysis/respira-
tion balance [23]. Additionally, HIF modulates components
implicated in the electron transport chain (ETC). The free en-
ergy required to produce ATP in mitochondria is obtained
from the oxidation of NADH and FADH2 by the mitochon-
drial ETC, a series of ﬁve multi-enzyme complexes (I–V)
through which electrons transfer from lower to higher reduc-
tion standard potentials. Oxygen is the ultimate electron accep-
tor leading to the formation of H2O in a reaction catalysed by
Cytochrome c OXidase (COX) the complex IV component of
the ETC. HIF was shown recently to bring about a swap from
COX4-1 to COX4-2 expression with the consequence of opti-
mising COX activity under hypoxia since COX4-2 is more eﬃ-
cient in transfer of electrons to oxygen. It is postulated that
this substitution protects cells from oxidative damage in hy-
poxia. The tip occurs through HIF up-regulating the expres-
sion of LON a mitochondrial protease that degrades the
protein COX4-1 and at the same time through HIF induction
of the COX4-2 gene [32]. The activity of the ETC of mitochon-
dria is also regulated by the tumour suppressor p53 through
the induction of synthesis of cytochrome c oxidase 2 (SCO2),
a component required in the assembly of the mitochondrial
COX complex of the ETC, in this way p53 maintains normal
cell respiration [33]. Yet another level of complexity of meta-
bolic regulation arises through HIF promotion of c-myc-med-
iated enhancing of mitochondrial biogenesis and thus
respiration [34] and mitochondrial homeostasis [35]. The
knockdown of LDH-A not only suppresses lactate production
in tumour cells but also increases oxygen consumption and
OXPHOS activity, thereby tipping back the glycolysis/respira-
tion balance [23].
Yet another key pathway implicated in nutrient utilisation,
the PI3K/Akt/mTOR pathway, acts on glucose metabolism.
When fully active the Akt protein kinase, in cells deﬁcient
for the tumour suppressor phosphatase and tensin homologue
(PTEN), can stimulate glycolysis through increased glucose
transport and hexokinase mobilisation [27]. At the same time
the activation of mTOR drives glucose catabolism through
the mitochondrial pathway and stimulates mitochondrial oxy-
gen consumption and oxidative capacity [36]. Through the
inhibition of mTOR (mammalian target of rapamycin), a ser-
ine/threonine protein kinase involved in regulating protein
translation, HIF-1 and nutrient deprivation negatively regulate
ATP consuming protein translation thus promoting cell sur-
vival through energy conservation [37,38]. In addition, it is
noteworthy that mTOR is inhibited by the upstream regulatorand tumour suppressor tuberous sclerosis complex (TSC1-
TSC2), which provides a link between metabolism and the
function of tumour suppressors.
Finally, components of the TCA cycle can inﬂuence the sta-
bility and activity of HIF by directly modulating the activity
of the oxygen sensors PHD proteins and FIH [39]. 2-Oxoglu-
tarate (2-OG) (a-ketoglutarate), a product of the TCA cycle
and amino acid catabolism, is a co-substrate of PHDs and
FIH. Thus it would be expected that a decrease in its concen-
tration would favour HIF-a stability and HIF activation. In
addition, the oxidative decarboxylation of 2-OG by the diox-
ygenases PHD and FIH leads to formation of succinate, a
competitive inhibitor of activity, which can be reversed by
an excess of 2-OG. Mutations in the mitochondrial enzymes
of the TCA cycle succinate dehydrogenase (SDH) and
fumarate hydratase (FH) have been described to promote
tumourigenesis (for review see [40]). SDH and FH are
tumour-suppressors and the former is directly link to the
respiratory chain. The mechanism leading to tumourigenesis
implicates the accumulation of succinate or fumarate, as a
result of competitive inhibition of, respectively, SDH or FH,
which then represses dioxygenase activity creating a ‘‘pseudo-
hypoxic’’ condition [41,42]. Pseudohypoxia stabilizes HIF-a
thereby inducing downstream genes such as vegf that promote
formation of highly vascularized tumours [40]. In addition, the
dioxygenase activity is dependent on Fe2+ and ascorbic acid as
co-factors and thus the oxidative status of the iron bound to
PHD proteins can regulate its activity [43]. Increased produc-
tion of reactive oxygen species (ROS) by mitochondria in
hypoxia promotes oxidation of Fe2+ to Fe3+ and provides a
mechanism to explain ROS-mediated stabilisation of HIF-1a
[44].6. Tumour acidosis and cellular pH regulation
The tumour extracellular pH (pHe) is reported to be more
acidic than that of non-malignant tissues; 6.2–6.8 for tumour
cells compared to 7.2–7.4 for normal cells (Fig. 7) [45]. This
is the consequence of the metabolic switch that produces not
only lactic acid but also CO2 and of their diminished vascular
dispersion due to a deﬁcient tumour vascular network. Correc-
tion of the intracellular pH (pHi) is considered to be necessary
for cancer cells to survive metabolic acidosis. Cellular pH
homeostasis brings into play a number of membrane located
transporters, exchangers, pumps and ecto-enzymes. Lactic acid
is excreted from cells via a H+/lactate cotransporter (mono-
carboxylate transporter, MCT), resulting in an increase in
the pHi (Fig. 7). The amiloride-sensitive Na
+/H+ Exchanger
(NHE-1), is also a major player in pHi homeostasis [46]. The
expression of the MCT4 [47], NHE1 [48] and NHE6 [31] iso-
forms have been shown to be up-regulated under hypoxic con-
ditions through transcriptional activation by HIF and the
exchange activity of NHE1 to be increased [47,49]. Carbonic
anhydrase (CA), an enzyme that catalyzes the reversible con-
version of CO2 to carbonic acid, is postulated to contribute
to the increase in the pHi of tumour cells via the uptake of
HCO3 through Cl
=HCO3 exchangers (Fig. 7) [50]. The mam-
malian CA family of zinc metalloenzymes (EC 4.2.1.1) is com-
posed of 14 isoforms that vary in activity and tissue
distribution [51,52]. CA IX and CA XII are localized in the
plasma membrane with ecto-activity. CA9 and CA12 are
Fig. 7. The multiple mechanisms through which HIF intervenes in pH homeostasis in tumour cells. The extracellular pH (pHe) of malignant cells is
lower than that of non-malignant cells, at least in part due to lactic acid and CO2 production. Lactate excretion from cells is enhanced by HIF-
mediated activation of the gene coding for the H+/lactate monocarboxylate transporter (MCT4) while HIF-mediated increased expression of the
ecto-enzyme carbonic anhydrase IX (CA IX) results in enhanced conversion of CO2 to HCO

3 , a weak base, and subsequent intracellular
alkalinization due to retrieval of HCO3 by members of the Na
+-dependent and -independent HCO3 transporters including the anion exchanger
(AE).
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carcinomas (RCC) and in multiple human cancers [21,50]. A
correlation between hypoxia, angiogenesis, HIF-1a and CA
IX expression in primary tumours and lymph node metastases
in breast cancer has been reported [53]. CA IX expression has
been correlated with poor prognosis and as such has been pro-
posed as a marker of an aggressive malignant phenotype [54–
56]. In addition to interacting with a number of membrane
exchangers and cotransporters the cytosolic CA II isoform
was shown to interact with MCT1 and to enhance the rate
of H+ ﬂux mediated by MCT1 via a non-enzymatic mechanism
[57]. It may thus be hypothesized that in hypoxia in a similar
manner to the CA II isoform, CA IX and XII function through
coupling to MCT protein(s) and to the superfamily of bicar-
bonate transporters, including the anion exchangers (AEs)
and the sodium bicarbonate co-tranporter (NBCs). In this
way cancer cells could maintain a more alkaline pHi that pro-
motes cell survival and proliferation. However, the implication
of CA in tumour progression and metastasis through modula-
tion of the pH requires further investigation.7. Tumour microenvironment in the balance towards
tumourigenesis and metastasis
Oncogenic transformation alone is not the only factor
important for in vivo tumourigenesis; the acidic microenviron-
ment is also a key determinant in cancer progression. This is
illustrated by the silencing of LDH-A in neu-initiated tumour
cells that leads to reduced tumour growth, as described above,
silencing switches pyruvate metabolism from the cytoplasmicto the mitochondrial pathway [23]. Studies on H-ras onco-
gene-transformed Chinese hamster lung ﬁbroblast defective
in pHi regulation through NHE-1 and/or aerobic glucose
metabolism [58] and into the Na+/H+ exchanger regulatory
factor, a factor that stimulates NHE-1 activity in breast cancer
cells, also suggest that the acidic microenvironment plays a
part in tumour progression and invasion [49]. It can be hypoth-
esized that cells that survive acidosis not only develop a growth
advantage but also become more aggressive with a propensity
to metastase. A low pHe can activate proteins such as matrix
metalloproteases that themselves are induced in hypoxia in a
HIF-dependent manner [59]. This promotes disruption of
cell–cell and cell–extracellular matrix (ECM) contacts that al-
low migration of cells through basement membranes and stro-
mal tissue into blood or lymph vessels to form metastatic foci.
Proteins of the ECM such as epithelial cadherin, selectins and
integrins may be inﬂuenced directly by HIF or indirectly by its
eﬀects on the tumour environment. Thus lactic acid could give
rise to adaptive processes and favour metastasis associated
with poor survival [60].
HIF also activates genes such as the c-met proto-oncogene
and the chemokine receptor CXCR4 that are involved in inva-
sion and metastasis [61,62]. It is noteworthy that the HIF-
dependent glycolytic enzyme phosphoglucose isomerase
(PGI) possesses cytokine and autocrine motility factor
(AMF) activity and that PGI/AMF is found to be up-regulated
in a number of cancers [63]. The cytokine action has been asso-
ciated with transformation, proliferation, angiogenesis, apop-
tosis, cell migration and metastasis. In addition, it has been
reported that tumours that are hypoxic posses a more meta-
static phenotype [8].
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The question as to whether HIF is pro-survival or pro-death
is an open question (for review [64]) since HIF activates genes
implicated in both, seemingly opposite, pathways [65]. How-
ever, when considering the number of genes the balance weighs
in on survival. Paradoxically, while hypoxia is the major stim-
uli regulating HIF activity, a number of other agents known to
promote cell proliferation or cell death also inﬂuence HIF
expression levels, stability and activity. The expression of
many of these proteins is also HIF mediated. Growth factors,
such as insulin-like growth factor, epidermal growth factor,
platelet growth factor and ﬁbroblast growth factor, hormones
such as the vasoactive angiotensin II and androgens, cytokines
like tumour necrosis factor-a and interleukin-1b, and the vaso-
active molecule NO all modulate HIF.
Even if HIF induces proteins such as Bcl-2/adenovirus EIB
19 kDa-interacting protein 3 (BNIP3) and its homolog Nip-3
like protein X (NIX), which are implicated in programmed cell
death, their overexpression alone may not be suﬃcient to bring
about cell death [64,66]. Additional conditions such as acidosis
or severe hypoxia may be required to sensitize cells to ensue
cell death [67,68]. HIF may also inﬂuence diﬀerent types of cell
death including apoptosis, necrosis and autophagy, which are
responsible for physiological and pathological clearing of cells
[69]. Apoptosis is an ATP-dependent mechanism that follows
either an extrinsic (death receptor) or intrinsic (mitochondrial)
pathway and brings into play the proteolytic activity of casp-
ases. When the level of ATP in cells is so low caspase-indepen-
dent ‘‘Accidental necrosis’’ occurs – referred to as accidental
because it arises in contact with cytotoxic agents. Autophagy
can be considered as a desperate survival strategy in response
to stress which in extreme conditions can end in cell death but
in less severe conditions could ensure survival. The mechanism
involves vacuolation of cellular components for lysosomal deg-
radation and recycling, a form of self-eating. Thus autophagy
may represent an early survival mechanism providing nutrients
to increase the ATP level giving the cell enough time to migrate
to a more nourishing area (yeast) or to initiate angiogenesis
and establishment of a new blood vessel network that eventu-
ally brings to the tumour oxygen and nutrients. In addition,
previously reported HIF-mediated pro-apoptotic gene prod-
ucts such as BNIP3 and BNIP3L may in fact exert a pro-sur-
vival action by inducing autophagy. These diﬀerent routes of
cell death may all contribute to reduce or promote tumour
progression, but the part that hypoxia and HIF play still needs
further clariﬁcation.9. Conclusions
HIF is emerging as a critical regulator of cancer cell metab-
olism and thus cell survival and metastasis. HIF by: (1)
repressing oxygen-consuming protein and lipid synthesis, (2)
increasing expression of proteins involved in anaerobic glucose
metabolism and pHi control, (3) repressing or optimizing mito-
chondrial oxidative respiration, (4) repressing PHD and FIH
activity through regulation of TCA cycle metabolic intermedi-
ates and (5) promoting angiogenesis, renders cancer cells more
eﬃcient in mobilizing glucose and thereby rapidly producing
substantial levels of ATP for survival, proliferation and migra-
tion.Classical chemotherapeutic approaches for treatment of can-
cer suﬀer from non-speciﬁc, toxic side eﬀects through the tar-
geting of not only malignant but also normal tissues. A
better understanding of tumour metabolism and of the reliance
on anaerobic glucose metabolism and the consequences for
malignant growth should make way for the development of
novel therapeutic agents that attack speciﬁcally tumour cells
and thus spare normal tissues [70]. Controlling hypoxic read-
justment of the pHi might also show promise in driving cells
to death [52]. Such drugs may also potentiate the cytotoxicity
of classical chemotherapy [71].
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